Styrelsen för XVIVO Perfusion beslutar om nyemission om högst ca. 181 miljoner kronor riktad till institutionella investerare
Nyemissionen är riktad till institutionella investerare och villkorad av godkännande från extra bolagsstämma
Read moreNyemissionen är riktad till institutionella investerare och villkorad av godkännande från extra bolagsstämma
Read moreThe share issue directed to institutional investors and is subject to approval from an extraordinary general meeting
Read moreEJ FÖR DISTRIBUTION DIREKT ELLER INDIREKT, INOM ELLER TILL USA, KANADA, AUSTRALIEN, SYDAFRIKA, JAPAN, HONGKONG, SCHWEIZ, SINGAPORE ELLER…
Read moreNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA,…
Read moreThe board of directors of Xvivo Perfusion AB (publ) (“Xvivo” or the “Company”) (NASDAQ OMX First North: XVIVO) has, pursuant to an authorization from the annual general meeting held on April 29, 2014, resolved to issue 1,950,000 new shares in Xvivo through a private placement directed to a group of qualified Swedish and international investors (the “Private Placement”). The Private Placement was announced on June 25, 2014 and was fully subscribed.
Read more